Biotech Values

[stuck_holder]

DNDN dilution...

Richard Hamm who was acting finance officer before Schiffman arrived on the scene, on the 3rd qtr cc on Nov 8 2006 (8 days before the Nov. 16th financing) responded to the following Charles Duncan question this way...

--------------------------------------------------------------------------------
Charles Duncan, JMP Securities - Analyst [10]
--------------------------------------------------------------------------------

"Final question is related to your balance sheet. Pretty well-managed cash in the period. As you look out to building commercial infrastructure and also building out manufacturing capacity, what do you think the guidance is going to look like for next year? And do you feel like you have enough cash to get the ball over the goal line?

--------------------------------------------------------------------------------
Rick Hamm, Dendreon Corporation - SVP, Corporate Development, General Counsel [11]
--------------------------------------------------------------------------------
We have enough cash to get through our BLA and through the FDA decision point. Clearly, if we get a positive approval from the FDA, we'll be looking to raise cash in order to enhance our commercialization and manufacturing build-out efforts."

http://www.investorshub.com/boards/read_msg.asp?message_id=14635720

this is "corporate speak" for we can't/won't discuss financings since disclosing info about them will likely directly impact the share price, and therefore the level of dilution...

by my calcs, they were running on fumes (for a development stage biotech) heading into the panel, and the fact they have laid off only 40 so far won't be enough cost-cutting if they don't partner soon...which to me translates to a financing announcement is imminent...